CN Patent

CN113521020B — 一种含有水溶性酸的瑞德西韦固体剂型

Assigned to Qilu Pharmaceutical Co Ltd · Expires 2023-05-02 · 3y expired

What this patent protects

本发明名称为一种含有水溶性酸的瑞德西韦固体剂型。属于药物制剂技术领域。具体涉及一种以具有抗病毒活性的化合物瑞德西韦为活性成份、包含水溶性酸的固体剂型。本发明制备的瑞德西韦固体剂型提高了溶出度和生物利用度，对于轻中度患者服用方便，增加了患者用药的顺应性，有较大的临床应用价值；此外，本发明制备的含水溶性酸的瑞德西韦固体剂型质量稳定、可控，便于工业化生产。

USPTO Abstract

本发明名称为一种含有水溶性酸的瑞德西韦固体剂型。属于药物制剂技术领域。具体涉及一种以具有抗病毒活性的化合物瑞德西韦为活性成份、包含水溶性酸的固体剂型。本发明制备的瑞德西韦固体剂型提高了溶出度和生物利用度，对于轻中度患者服用方便，增加了患者用药的顺应性，有较大的临床应用价值；此外，本发明制备的含水溶性酸的瑞德西韦固体剂型质量稳定、可控，便于工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN113521020B
Jurisdiction
CN
Classification
—
Expires
2023-05-02
Drug substance claim
No
Drug product claim
No
Assignee
Qilu Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.